Hualing Technology Secures Hundreds of Millions in Series A Funding to Advance SaaS-Based Pharmaceutical Retail Management Solutions

Recently,Suzhou Hualing Technology Co., Ltd. (hereinafter referred to as “Hualing Technology”) announced the completion of its Series A financing round, amounting to hundreds of millions of yuan. The round was led by Shenzhen Capital Group, with participation from Hongtu Beili, Xiongdi Lian, and other institutions.. The funds raised will be used for the research and development of digital platforms, market expansion, and the establishment of innovative business ventures.

Hualing Technology, established in June 2021, is dedicated to providing continuously iterated operational management solutions based on SaaS to customers in pharmaceutical retail and related fields through a comprehensive digital platform. While helping customers improve efficiency, the company offers sustained support across three dimensions—desirability, accessibility, and affordability—to enable them to embrace future business possibilities within the industry, thereby delivering long-term, companion-style services that foster continuous business growth.

Core team members possess over 20 years of industry management and operational experience, with expertise in ERP implementation and digital transformation for more than 10,000 pharmacies.

In addition to its Suzhou headquarters, Hualing Technology has established three product and R&D centers in Changsha, Chengdu, and Nanjing. Since its inception, the company’s product brand"Pharmaceutical Ethics"Continuously refined the breadth and depth of business scenarios, as well as the application and value of technical methods, earning widespread customer recognition and sustained support from all stakeholders.

Wu Xinghua, Chairman of Hualing Technologystated: “The core team of Hualing comprises veterans of the pharmaceutical retail industry, who have been deeply involved in every critical milestone of the sector’s development. Some members participated in the early exploration and establishment of organizational structure, standardization, and informatization during the initial phase of the industry’s scaled growth, fostering a culture and habit of meticulous business analysis and relentless pursuit of efficiency. Throughout their continuous entrepreneurial journey, the core team has gained a profound understanding of each other’s humility and perseverance, engaging in mutual learning and broadening their horizons. This has cultivated trust and synergy grounded in questioning and discovery, inclusiveness and absorption, as well as responsibility and honor. It is precisely because of these accumulations that we have been fortunate to seize the industry-wide opportunity for comprehensive digital transformation, aiming to make new contributions to the sector with a mindset of creation and service.”

“Digitalization is an ongoing process. SaaS-based services represent a long-term commitment to our customers, entailing significant responsibilities and a long journey ahead. Hualing Technology itself will continue to learn and grow. We are deeply grateful for Shenzhen Capital Group’s recognition of our team and project. This endorsement not only reinforces our sense of honor and responsibility but also bolsters our confidence. Investors who are benevolent and broad-minded, and who possess both the willingness and capability to voice differing perspectives, are our strong friends and steadfast supporters,” said Wu Xinghua.

Dr. Zhou Yi, General Manager of the Shenzhen Capital Group Hongtu Medical and Health Industry FundIt stated, “Informatization and digitalization are the inevitable path for cost reduction and efficiency improvement in the pharmacy retail industry. With decades of deep cultivation in the pharmaceutical retail sector, the Hualing Technology team boasts extensive experience and profound industry insights. We believe that Hualing can empower clients to achieve multi-party win-win outcomes through its digital management solutions.”

Shenzhen Capital Group (SCGC), established in 1999, is committed to its mission of discovering and empowering great enterprises. Dedicated to identifying and nurturing innovative value, SCGC has evolved into a comprehensive investment group with venture capital at its core. The company currently has a registered capital of RMB 10 billion and manages assets totaling approximately RMB 425.8 billion. As of October 31, 2022, SCGC ranked among the industry leaders in both the number of portfolio companies and the number of listed investee companies: it had invested in 1,496 projects, with cumulative investments amounting to approximately RMB 90 billion. Among these, 233 portfolio companies have been listed on 17 major capital markets worldwide, and 453 projects have achieved exit (including IPOs).